The Food and Drug Administration on Thursday cleared the most popular nicotine pouch in the United States to stay on the market after the product proved to be a safer alternative for adults who smoke cigarettes, saying the benefits outweigh the possible risks to young people.

The agency said Philip Morris International’s Zyn pouches carry a lower risk for cancer and other serious health conditions than traditional dipping tobacco or cigarettes.

Recommended Stories

FDA’s anti-smoking strategy ignores millions of Americans

House Republicans press FDA to expedite approval process for smoke-free tobacco products

The EU should follow the FDA’s harm-reduction strategy